Abstract:Valentina Perrone, 1 Serena Losi, 2 Silvia Sabatino, 2 Maurizio Mezzetti, 3 Melania Dovizio, 1 Diego Sangiorgi, 1 Luca Degli Esposti 1 1 CliCon S.r.l., Società Benefit-Health Economics and Outcomes Research, Bologna, 40137, Italy; 2 Eli Lilly Italy S.p.A, Sesto Fiorentino, Italy; 3 Eli Lilly Italy S.p.A, Rome, Italy Correspondence: Valentina Perrone, CliCon S.r.l., Società Benefit-Health Economics and Outcomes Research, Via Murri 9, Bologna, 40137, Italy, Tel +39 544 38393, Fax +39 544 212699, Email Purpose: An Italian real-world retrospective study was conducted in patients with psoriasis (PSO) to evaluate their characteristics, treatment patterns, and biological/targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) drug utilization. Patients and Methods: The retrospective analysis was carried out on real-world data collected from administrative databases of selected Italian health-departments; the dataset covered approximately 22% of the Italian population. PSO patients (identified by PSO hospitalization, and/or active exemption code and/or a topical anti-psoriatic medication prescription) were included. In prevalent patients identified during 2017– 2018-2019-2020, baseline characteristics and treatment patterns were investigated. Moreover, b/tsDMARD drug utilization (focusing on persistence, monthly dosage, and mean duration between prescriptions) was evaluated in bionaïve patients included during 2015 and 2018. Results: PSO was diagnosed in 241,552 (in 2017), 269,856 (in 2018), 293,905 (in 2019) and 301,639 (in 2020) patients. At the index date, almost 50% of patients had not received systemic medications, and 2% had received biological treatment. Among the b/tsDMARD-treated patients, a decrease in the use of tumour necrosis factor (TNF) inhibitors (60.0– 36.4%, from 2017 to 2020) and an increase in the use of interleukin (IL) inhibitors (36.3– 50.6%, from 2017 to 2020) were observed. In 2018, the persistence rates of TNF inhibitors and IL inhibitors in bionaïve patients ranged from 60.8– 79.7% and 83.3– 87.9%, respectively. Conclusion: This real-world study of PSO drug utilization in Italy showed that a significant number of patients were not treated with systemic medications and only 2% of patients were treated with biologics. An increase in the use of IL inhibitors and a decrease in the prescription of TNF inhibitors over years were found. Patients treated with biologics were highly persistent with treatment. These data provide insight into routine clinical practice for PSO patients in Italy, suggesting that the optimization of treatment for PSO still represents an unmet medical need. Keywords: psoriasis systemic medications, psoriasis biological drugs, TNF inhibitors, IL inhibitors, treatment optimization, real world evidence Psoriasis (PSO) is a chronic inflammatory skin disease with a strong genetic predisposition and pathogenic autoimmune mechanisms. The worldwide prevalence is approximately 2% but varies according to region, reaching up to 11% among Caucasian and Scandinavian populations. 1 The prevalence of PSO among the Italian population is estimated to vary from 1.8% to 3.1%. 2 The dermatologic manifestations of PSO vary; the most prevalent is psoriasis vulgaris, also called plaque-type psoriasis. It is characterized by erythematous, often pruritic plaques covered with silvery scales. While PSO can occur at any age, two peaks of disease onset have been described: the first between 20 and 30 years, and the second between 50 and 60 years, affecting men and women equally. 3 Depending on the severity and localization of the psoriatic lesions, patients may suffer from physical and psychological discomfort and significant disability, which negatively affects the patient's quality of life. 4,5 PSO typically affects the skin but may also affect the joints and has been associated with a number of other inflammatory diseases, such as psoriatic arthritis (PsA). Skin manifestations generally precede PsA, which shares the inflammatory chronicity of PSO and requires systemic therapy due to potential destructive progression. PsA develops in up to 40% of PSO patients, 6–9 and its incidence increases with time after PSO onset, reaching up to 20% after 30 years. 10,11 In addition, PSO patients have an increased incidence of metabolic syndrome manifestations 12 and cardiovascular disease (CVD). 13 Treatment options available to manage psoriatic disease include topical therapy, phototherapy, oral treatment, and biologic therapy. 14 The choice of treatment is largely based on disease severity, the presence of comorbid conditi -Abstract Truncated-

Analysis of the prevalence of ankylosing spondylitis and treatment patterns and drug utilization among affected patients: an Italian real-world study

Pattern of drug use in patients with psoriatic arthritis in Italy: study in a real-world setting

Real-World Adherence and Drug Survival of Biologics among Patients with Ankylosing Spondylitis

The burden of ankylosing spondylitis in Spain

Analysis of Drug Utilization in Patients with Psoriasis: A Real-World Retrospective Study Among the Italian Population

Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey

AB1143 BURDEN OF GLUCOCORTICOIDS AMONG RHEUMATOID ARTHRITIS PATIENTS AT DIFFERENT STAGES OF DISEASE-MODIFYING ANTIRHEUMATIC DRUG MANAGEMENT

AB0679 Comparison of Two Different Ethnic Groups of As Patients: Table 1.

Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis

Prescribing Pattern and Safety Profile of Biological Agents for Psoriasis in Real-World Practice: A Four-Year Calabrian Pharmacovigilance Analysis

Annual trends in pain management modalities in patients with newly diagnosed autoimmune rheumatic diseases in the USA from 2007 to 2021: an administrative claims-based study

Biological treatment in ankylosing spondylitis in the Nordic countries during 2010–2016: a collaboration between five biological registries

The Trend of Targeted Therapies in Chinese Patients With Ankylosing Spondylitis: Results From a Real-Life Survey

Opioid use surrounding diagnosis and follow-up in patients with ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis: Results from US claims databases

Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases

Long-Term Real-Life Data from Five Italian Referral Centers

Switching related to inefficacy in biologics and targeted synthetic therapies for psoriatic arthritis: a comparative real-life study

Primary Sjögren's syndrome in Italy: Real-world evidence of a rare disease through administrative healthcare data

Patient-reported Flares in Ankylosing Spondylitis: A Cross-sectional Analysis of 234 Patients

Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry

Opioid Use in Patients with Ankylosing Spondylitis Is Common in the United States: Outcomes of a Retrospective Cohort Study